[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"schizophrenia-1-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:schizophrenia-1-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,49,76,105,133,162,194,221,249,275,305,328,359,384],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100605036","online-intervention-to-improve-motivation-100605036",false,"NCT07157293","Online Intervention To Improve Motivation","An Online Intervention To Enhance Motivation and Goal-Directed Behavior","Online Mot","Inclusion Criteria:\n\n* Diagnosis of schizophrenia or a related psychotic disorder\n* Meeting criteria for being at clinical high risk for psychosis\n\nExclusion Criteria:\n\n* Does not have access to a computer each week","ALL","18 Years","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Participants will complete one online intervention lasting 12 weeks. Each week, they will be asked to complete a 20-30 minute session online. The intervention is targeting improved mood and positive affect in order to support increases in motivation and goal-directed behavior. Before and after the intervention, participants will be asked to complete measures to assess symptoms, mood, and behavior.",[28,29,30],"Schizophrenia Prodromal","SCHIZOPHRENIA 1 (Disorder)","Psychosis",[32,33,34,35],"negative symptoms","schizophrenia","psychosis","digital health","NOT_YET_RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":22},"2026-08",{"date":44,"type":22},"2028-08",{"name":46,"class":47},"University of Alabama at Birmingham","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100641339","the-effect-of-act-based-nursing-interventions-on-social-cognition-emotion-regulation-and-psychological-flexibility-in-patients-with-schizophrenia-100641339","NCT07661225","The Effect of ACT-Based Nursing Interventions on Social Cognition, Emotion Regulation and Psychological Flexibility in Patients With Schizophrenia","The Effect of Acceptance and Commitment Therapy (ACT)-Based Nursing Interventions on Social Cognition, Emotion Regulation and Psychological Flexibility in Individuals With Schizophrenia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Diagnosed with schizophrenia (ICD-10\u002FDSM-5) and followed at Erzincan Community Mental Health Center (TRSM)\n* Registered at Erzincan TRSM\n* Duration of schizophrenia diagnosis of at least 6 months\n* No cognitive or sensory (hearing\u002Fvisual) deficit that would prevent participation\n* Literate\n* Provides written informed consent to participate\n\nExclusion Criteria:\n\n* Comorbid psychiatric diagnosis other than schizophrenia\n* Active acute psychotic episode at enrollment\n\nDiscontinuation \u002F Withdrawal Criteria\n\n* Voluntary withdrawal from the study\n* Acute psychotic relapse during the study period\n* Additional psychiatric diagnosis during the study period\n* Radical change in medication type or dosage during the study period\n* Incomplete responses on data collection forms\n* Completion of less than 80% of assigned homework",{"count":57,"type":22},64,[25],"This randomized controlled trial aims to evaluate the effect of Acceptance and Commitment Therapy (ACT)-based nursing interventions on social cognition, emotion regulation, and psychological flexibility in individuals diagnosed with schizophrenia. The study will be conducted at Erzincan Community Mental Health Center (TRSM) between October 2026 and January 2027. A total of 64 participants (32 experimental, 32 control) will be recruited from schizophrenia patients registered at the center. The experimental group will receive 8 structured group sessions based on ACT principles integrated into nursing practice (45-60 minutes per session, once weekly), while the control group will receive routine care only. Pre-test and post-test measurements will be obtained using the Observable Social Cognition Rating Scale (OSCARS), the Difficulties in Emotion Regulation Scale-Brief Form (DERS-16), and the Acceptance and Action Questionnaire-II (AAQ-II).",[29],[62,63,64,65,66],"Acceptance and Commitment Therapy","ACT-based nursing intervention","Social cognition","Emotion regulation","Psychological flexibility","2026-06-18",{"date":69,"type":40},"2026-06-22",{"date":71,"type":22},"2026-10",{"date":73,"type":22},"2027-01",{"name":75,"class":47},"Ataturk University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100641246","act-based-psychoeducation-for-caregivers-of-patients-with-schizophrenia-100641246","NCT07656558","ACT-Based Psychoeducation for Caregivers of Patients With Schizophrenia","The Effect of Acceptance and Commitment Therapy-Based Psychoeducation Applied to Caregivers of Schizophrenia Patients Attending the Community Mental Health Center on Emotional Expression, Perceived Family Burden, and Psychological Flexibility: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Living with an individual diagnosed with schizophrenia who has been followed and actively receiving services from a Community Mental Health Center for at least one year.\n* Being the primary caregiver responsible for the care of the individual diagnosed with schizophrenia.\n* Having been involved in the care and treatment of the individual diagnosed with schizophrenia for at least 12 months prior to the study.\n* Being between 18 and 65 years of age.\n* Being literate.\n* Being able to speak and understand Turkish.\n* Willing to participate in the study and providing informed consent.\n\nExclusion Criteria:\n\n* Having a medically diagnosed psychiatric disorder.\n* Having a diagnosis of an organic mental disorder or intellectual disability.\n* Having a physical impairment that may interfere with participation in the study or data collection process (e.g., hearing or speech impairment).",true,{"count":21,"type":22},[25],"This randomized controlled trial aims to examine the effects of an Acceptance and Commitment Therapy (ACT)-based psychoeducation program on expressed emotion, perceived family burden, and psychological flexibility among caregivers of patients with schizophrenia attending a Community Mental Health Center.\n\nThe main questions this study aims to answer are:\n\n* Does ACT-based psychoeducation reduce expressed emotion among caregivers of patients with schizophrenia?\n* Does ACT-based psychoeducation reduce perceived family burden among caregivers of patients with schizophrenia?\n* Does ACT-based psychoeducation improve psychological flexibility among caregivers of patients with schizophrenia?\n\nResearchers will randomly assign eligible caregivers to either an intervention group receiving an 8-session ACT-based psychoeducation program or a control group receiving routine care.\n\nParticipants will:\n\n* Complete assessment measures before the intervention (pre-test).\n* Participate in 8 ACT-based psychoeducation sessions if assigned to the intervention group.\n* Continue receiving routine care if assigned to the control group.\n* Complete assessment measures immediately after the intervention (post-test).\n* Complete follow-up assessments at 1 month and 3 months after the intervention.",[29],[62,89,90,91,92,93,94,95,96],"Psychoeducation","Community Mental Health Center","Family Caregiver","Expressed Emotion","Family Burden","Psychological Flexibility","Randomized Controlled Trial","Schizophrenia","2026-06-14",{"date":67,"type":40},{"date":100,"type":22},"2026-07-01",{"date":102,"type":22},"2027-01-15",{"name":104,"class":47},"Aydin Adnan Menderes University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100642923","precision-hd-tacs-for-enhancing-sensory-experience-in-schizophrenia-100642923","NCT07632261","Precision HD-tACS for Enhancing Sensory Experience in Schizophrenia","Precision HD-tACS-Based Therapy for the Qualitative and Phenomenological Enhancement of Sensory Experiences in Schizophrenia","TherACles","Inclusion Criteria for control group and patient:\n\n* Be aged 18 to 65 years inclusive.\n* Have read and understood the study information sheet.\n* Be affiliated with a social security system or be a beneficiary.\n* Have normal or corrected-to-normal vision (glasses or contact lenses).\n\nExclusion Criteria for control group :\n\n* Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field.\n* Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.)\n* Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.)\n* Legal incapacity (under guardianship, conservatorship, or judicial\u002Fadministrative detention) or inability to provide informed consent.\n* Major psychiatric disorders (excluding tobacco use disorder).\n* Neurological disorders.\n* Severe somatic disorders that could interfere with participation.\n* Uncorrected visual impairments.\n* Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.).\n* Presence of any psychiatric disorder.\n* Under legal protection (guardianship or conservatorship).\n\nExclusion Criteria - Patient Group\n\nA potential patient participant will be excluded if they have:\n\n* Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field.\n* Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.)\n* Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.)\n* Legal incapacity (under guardianship, conservatorship, or judicial\u002Fadministrative detention) or inability to provide informed consent.\n* Major psychiatric disorders other than schizophrenia (excluding tobacco use disorder).\n* Neurological disorders.\n* Severe somatic disorders that could interfere with participation.\n* Uncorrected visual impairments.\n* Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.).",{"count":114,"type":22},80,[25],"To ensure unified sensory perception, the brain must link information from different senses across time and space. This unification of perception often referred to as a perceptual \"binding constraint\" is a prerequisite for any organized perception. Patients with schizophrenia exhibit deficits in the spatiotemporal binding of sensory information . Electroencephalography (EEG) studies highlight the role of delta-theta oscillatory dynamics (2-8 Hz) in neuronal entrainment processes underlying spatiotemporal binding, which enables the formation of a coherent and organized perceptual representation . These same dynamics are disrupted in schizophrenia .\n\nIn tasks assessing perceptual binding, such alterations manifest as widened temporal binding windows, reflecting impaired temporal structuring of visual events. Physiologically, these disruptions may stem from impaired feedback mechanisms within the cortico-cerebello-thalamo-cortical (CCTC) loop. Schizophrenia patients also exhibit functional and structural deficits in the pulvinar and frontal cortex, key nodes of the CCTC loop .\n\nRecent technical advances in transcranial neurostimulation have reinforced its potential as a therapeutic tool. High-definition transcranial alternating current stimulation (HD-tACS) now enables individualized modulation of pre-identified neural networks , including targeted interventions for schizophrenia . Based on a personalized stimulation protocol, this research project proposes precision HD-tACS therapy, tailored for each patient according to their delta-theta peak frequency measured via EEG and the optimal functional stimulation site identified with functional MRI (fMRI). Stimulation will be applied functionally, i.e., while the patient performs a cognitive task.\n\nStructural connectivity alterations have been observed in fronto-thalamic, thalamo-cingulate, and cortico-cerebellar pathways in schizophrenia, potentially underpinning temporal and spatial binding deficits. Assessing the integrity of the CCTC loop with diffusion tensor imaging (DTI) will allow quantification of fiber coherence and white matter density connecting cortical and subcortical regions within this network.To evaluate both baseline perceptual deficits and the potential improvements induced by stimulation, a control group of healthy participants will be included.",[29,118],"Sensory Perceptual Characteristics",[120,121,122,123],"perceptual binding","sensory perception","transcranial stimulation","tACS","2026-06-05",{"date":126,"type":40},"2026-06-08",{"date":128,"type":22},"2026-06-15",{"date":130,"type":22},"2030-05-01",{"name":132,"class":47},"Hôpital le Vinatier",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":48},"100638199","developing-a-virtual-reality-assisted-intervention-for-emotion-regulation-difficulties-in-psychosis-100638199","NCT07623928","Developing a Virtual Reality-assisted Intervention for Emotion Regulation Difficulties in Psychosis","MANaging emOtions in Everyday Life Using Virtual REality (MANOEUVRE): Developing a VR-assisted Intervention for Emotion Regulation Difficulties in Psychosis","MANOEUVRE","Inclusion Criteria:\n\n* Currently under the care of South London and Maudsley (SLaM) National Health Service (NHS) outpatient services.\n* Clinical diagnosis of psychosis (schizophrenia spectrum disorder) (as assessed by their clinical team)\n* Willing to have the interview audio recorded (if taking part in post therapy interview)\n* Willing and able to provide informed consent to participate in the study (as assessed by their clinical team)\n\nExclusion Criteria:\n\n* Clinical presentation (e.g., immediate serious risk to self) (as assessed by their clinical team)\n* History of photosensitive epilepsy",{"count":142,"type":22},15,[25],"Supporting people with psychosis to manage their emotions using virtual reality\n\nMany people who have experienced psychosis feel overwhelmed by their emotions. Emotions get in the way of doing what matters to them. They want support to manage emotions differently. There is evidence that people with psychosis find talking therapies that teach skills for managing emotions helpful. People said it helped them to understand and manage their emotions. However, they also wanted more help to apply skills they learned to their lives.\n\nIt is hard to help people to use therapy skills in real-life situations. Therapists cannot be present when the skills are needed. One solution is to use virtual reality (VR) to bridge the gap between the clinic and real-life. VR involves using a headset to see and hear a very life-like computer-generated simulation of everyday life situations. People with psychosis find VR therapies engaging and helpful. It can feel safer to try things out in VR.\n\nGuided by the feedback of people with psychosis, this research will evaluate a novel therapy to help people with psychosis manage their emotions. Face-to- face therapy will be combined with VR so that people can practice emotion regulation skills safely with \"live\" coaching from a therapist. This should support people to use these skills when they need them.\n\nFifteen people with psychosis will be offered the therapy. Everyone will be asked what they think of it and complete questionnaires before and after therapy to see what impact it had on their lives.\n\nA lived experience advisory group will support all aspects of the research process.",[30,29,146],"Schizophrenia and Related Disorders",[65,30,148,149,150,151,152],"Virtual reality","Schizophrenia spectrum disorders","Virtual reality exposure therapy","Psychotherapy","Dialectical behaviour therapy","2026-05-28",{"date":155,"type":40},"2026-06-03",{"date":157,"type":22},"2027-09-01",{"date":159,"type":22},"2028-11-01",{"name":161,"class":47},"King's College London",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":172,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":4},"100639781","phase-2-confirmatory-trial-of-gamma-neurofeedback-to-improve-working-memory-in-schizophrenia-100639781","NCT07592169","Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophrenia","Confirmatory Efficacy Trial to Confirm the Effects of Gamma EEG-Neurofeedback on Working Memory in Schizophrenia","Inclusion Criteria:\n\n* 1\\. DSM-5 diagnosis of schizophrenia or schizoaffective disorder, confirmed by the Structured Clinical Interview for DSM-5 (SCID-5) 2. Age 18-55 years 3. Clinically stable: no psychiatric hospitalization in the 3 months prior to enrollment 4. No change in antipsychotic medication type or dosage within 4 weeks prior to baseline assessment 5. Ascertained to be clinically and medically stable by a study investigator 6. Does not meet DSM-5 diagnostic criteria for bipolar disorder or current major depressive episode 7. No electroconvulsive therapy (ECT) within 6 months of baseline assessment 8. Able to read and speak English (corrected vision or hearing aids acceptable) 9. Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* 1\\. Self-reported history of seizure disorder 2. Diagnosed with multiple sclerosis 3. History of stroke or major vascular disease, including insulin-dependent diabetes mellitus 4. HIV\u002FAIDS diagnosis 5. Current (not past) major depressive episode 6. Substance use disorder other than nicotine use disorder or caffeine use disorder in the past year 7. Brain cancer (primary or metastatic) 8. Prior head injury involving loss of consciousness 9. Inability to read or speak English 10. Color blindness that interferes with administration of study assessments 11. Neuropsychological or cognitive testing in the past 6 months using the same measures as this study 12. Score on Letter-Number Sequencing greater than 1 standard deviation above the age-normed mean","55 Years",{"count":171,"type":22},104,[173],"PHASE2","This study is a confirmatory, double-blind, placebo-controlled randomized clinical trial (RCT) testing whether gamma EEG neurofeedback (EEG-NFB) improves working memory in adults with schizophrenia or schizoaffective disorder. Participants are randomly assigned to receive either active gamma EEG-NFB (real-time feedback of frontal gamma brain activity) or sham EEG-NFB (false pre-recorded feedback), twice weekly for 12 weeks. Working memory (N-back task), brain gamma coherence, and everyday community functioning are assessed at baseline, mid-treatment, end of treatment, and follow-up.",[29,176],"Schizoaffecitve Disorder",[33,178,179,180,181,182,183,184],"neurofeedback","EEG","gamma oscillations","working memory","randomized controlled trial","n-back","community functioning","2026-05-11",{"date":187,"type":40},"2026-05-18",{"date":189,"type":22},"2026-06-01",{"date":191,"type":22},"2030-05-31",{"name":193,"class":47},"University of California, San Diego",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":201,"enrollmentInfo":202,"targetDuration":204,"studyType":205,"phases":4,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":4},"100639324","comparison-of-the-italian-and-us-forensic-models-for-dual-diagnosis-offenders-a-3-year-longitudinal-study-100639324","NCT07585656","Comparison of the Italian and U.S. Forensic Models for Dual-diagnosis Offenders: a 3-year Longitudinal Study","Comparison of the Italian and US Forensic Models Regarding Dual Diagnosis Offenders: a 3-year Longitudinal Study","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Individuals admitted to forensic psychiatric care in Italy or California.\n* Presence of a diagnosed mental disorder according to DSM-5 \u002F ICD criteria.\n* Presence of a current or lifetime Substance Use Disorder, consistent with a dual-diagnosis condition.\n* Placement in one of the study settings:\n\nItaly: REMS or other forensic\u002Fcommunity facilities under custodial or non-custodial security measures; California: Department of State Hospitals forensic facilities.\n\n* Ability to provide written informed consent, or consent provided through a legal guardian when applicable.\n* Availability for longitudinal follow-up at 12, 24, and 36 months.\n\nExclusion Criteria:\n\n* Absence of a confirmed psychiatric disorder.\n* Absence of current or lifetime Substance Use Disorder.\n* Non-forensic psychiatric patients without criminal justice involvement.\n* Severe cognitive impairment or neurological condition preventing valid assessment.\n* Acute medical or psychiatric instability that makes participation temporarily impossible.\n* Inability to complete the assessment procedures, even with support or adapted administration.\n* Refusal to participate or withdrawal of informed consent. Insufficient clinical, forensic, or follow-up data for longitudinal analysis.","75 Years",{"count":203,"type":22},600,"3 Years","OBSERVATIONAL","This study aims to compare the Italian and U.S. forensic models in the treatment of offenders with dual diagnosis through a three-year longitudinal design. In Italy, the closure of Judicial Psychiatric Hospitals following Law 81\u002F2014 led to the establishment of a community-based forensic system centered on REMS (Residences for the Execution of Security Measures), integrated within the National Health Service. This model seeks to limit institutionalization and promote rehabilitative pathways in community settings. However, it continues to face challenges related to limited bed availability, waiting lists, and the complex management of social dangerousness. In contrast, the U.S. system, particularly in California, is characterized by high-security forensic psychiatric hospitals with large capacities, but also presents issues such as prolonged hospitalizations, an aging patient population, and a high prevalence of substance use disorders.\n\nDual diagnosis, defined as the co-occurrence of psychiatric disorders and substance use disorders, is highly prevalent in forensic populations and is associated with increased clinical complexity, higher risk of recidivism, and poorer treatment outcomes. Neurobiological and psychological mechanisms underlying addiction-including dysfunctions in the dopaminergic reward system, craving processes, and impairments in executive functioning-contribute to reduced behavioral control and increased impulsivity. Theoretical models such as the self-medication hypothesis and multifactorial frameworks suggest that substance use may both exacerbate psychiatric symptoms and represent an attempt to regulate them.\n\nGiven these complexities, integrated treatment approaches that combine psychiatric care and addiction interventions are essential, particularly in forensic settings. The present study includes offenders with mental illness in forensic care systems in Italy and California, encompassing both custodial and non-custodial settings. Participants will be followed over a three-year period, with assessments conducted at 12, 24, and 36 months. The methodology involves the use of standardized instruments to evaluate psychopathological severity, global functioning, risk of violent recidivism, protective factors, treatment adherence, impulsivity, and substance use. Data on clinical outcomes, antisocial behaviors, and discharge conditions will also be collected.\n\nThe primary objectives of the study are to describe and compare the clinical, demographic, and criminological profiles of forensic populations with dual diagnosis; to examine treatment pathways and outcomes; to identify indicators of treatment effectiveness; and to evaluate both risk and protective prognostic factors, as well as their predictive value for recidivism and clinical trajectories.\n\nThe expected impact of the study lies in improving the understanding of differences between community-based and hospital-based forensic models, with the goal of identifying integrated strategies capable of enhancing rehabilitation, reducing recidivism, and improving long-term outcomes. Findings may contribute to the development of more effective and individualized treatment approaches, as well as inform health and judicial policies aimed at better integrating clinical care and risk management in dual diagnosis forensic populations.",[29,208],"Substance Abuse",[210,211,212],"forensic treatment","SUD","forensic psychiatry","2026-05-06",{"date":215,"type":40},"2026-05-14",{"date":189,"type":22},{"date":218,"type":22},"2029-06-01",{"name":220,"class":47},"University of Bari",{"id":222,"slug":223,"hasResults":11,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":228,"maxAge":229,"enrollmentInfo":230,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":232,"conditions":233,"keywords":234,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":48},"100635930","multi-target-tms-for-schizophrenia-negative-symptoms-100635930","NCT07559084","Multi-target TMS for Schizophrenia Negative Symptoms","Development of a Multi-target Transcranial Magnetic Intervention Technique for Negative Symptoms of Schizophrenia","Inclusion Criteria:\n\n1. Outpatients or inpatients at the Department of Psychiatry, Shanghai Mental Health Center;\n2. Meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria for first-episode schizophrenia (diagnosed using the Structured Clinical Interview for DSM-5, SCID-5); disease duration less than 5 years at enrollment;\n3. Male or female aged 16-45 years;\n4. Education duration ≥ 9 years;\n5. Stable medication regimen for at least 6 weeks prior to baseline visit and throughout the study period; psychiatric symptoms generally stable within 1 month prior to baseline visit;\n6. Participants and their guardians can understand and sign written informed consent;\n7. Total score on the PANSS Negative Symptom subscale (PANSS-N) \\> 15, and at least one item score ≥ 3.\n\nExclusion Criteria:\n\n1. Current or lifetime psychiatric disorders as determined by SCID-5 assessment;\n2. Severe or unstable physical illnesses, including: neurological disorders (delirium, dementia, stroke, epilepsy, migraine, etc.), congestive heart failure, angina pectoris, myocardial infarction, arrhythmia, hypertension, hyperglycemia, malignant tumors, and immunocompromised conditions;\n3. Alcohol abuse within 30 days prior to the study or alcohol\u002Fdrug dependence within 6 months prior to the study; participation in any clinical trial within 30 days prior to baseline;\n4. Pregnant or breastfeeding women;\n5. Intellectual disability (IQ \\\u003C 70).","16 Years","45 Years",{"count":57,"type":22},[25],"This randomized controlled trial (RCT) is the first to evaluate the efficacy and safety of a multi-target TMS protocol targeting the left dorsolateral prefrontal cortex (L-DLPFC), left inferior parietal lobule (L-IPL), and right orbitofrontal cortex (R-OFC) for negative symptoms of schizophrenia.",[29],[33,235,236,237,238],"TMS","repetitive transcranial magnetic stimulation","rTMS","TBS","RECRUITING","2026-04-26",{"date":242,"type":40},"2026-04-30",{"date":244,"type":22},"2026-05-01",{"date":246,"type":22},"2028-01-30",{"name":248,"class":47},"Shanghai Mental Health Center",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":23,"phases":259,"briefSummary":261,"conditions":262,"keywords":263,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":271,"leadSponsor":273,"locationsCount":48},"100625508","phase-1-a-petmri-study-of-cobenfy-on-dopamine-transmission-in-schizophrenia-100625508","NCT07423546","A PET\u002FMRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","A Multimodal PET\u002FMRI Study of Cobenfy on Dopamine Transmission in Schizophrenia","Inclusion Criteria:\n\n1. Individuals aged 18 to 50, inclusive at screen\n2. Capable of understanding the study procedures and able to provide informed consent\n3. Diagnosed with schizophrenia, schizoaffective, or schizophreniform disorder\n4. Antipsychotic free at Visit 1 (by choice and for reasons unrelated to the study), and for at least 3 weeks (4 for aripiprazole, Cobenfy or LAIs) at the time of the baseline PET scan, inclusive of any antipsychotic-free time prior to consent\n5. PANSS total score \\> 80 and \\\u003C 120\n6. Willing to use qualified methods of contraception (listed in section 5.3) for the study duration (for women of childbearing potential only)\n7. Stable dosing of herbal\u002Fdietary supplements for at least 6 weeks at the time of the first dose of Cobenfy and willingness to avoid products with known hepatotoxic ingredients (e.g., green tea extract, kratom, ashwagandha).\n\nExclusion Criteria:\n\n1. Diagnosis of moderate or severe substance use disorder within the previous month (from first PET scan)\n2. A history of poor or inadequate response to Cobenfy for any reason, hypersensitivity to Cobenfy or trospium or no justifiable reason to expect improvement on Cobenfy, or treatment with Cobenfy within 4 weeks of the first PET Scan\n3. EKG abnormality that is clinically significant including a QT interval \\> 450 msec for men and \\> 470 msec for women, as corrected by the Fridericia formula (QTcF)\n4. Pregnant or breast-feeding women. Women of child-bearing potential must have a negative serum β-hCG pregnancy test at Visit 1, must have been using an acceptable method of contraception (section 5.3) for 30 days before the study, and must agree to do so for the whole study and 30 days after (unless post-menopausal or surgically sterile)\n5. Any clinically significant or unstable medical illness, condition, or disorder that is anticipated to potentially compromise participant safety on study medication, including (but not necessarily limited to) the following: urinary retention, moderate or severe hepatic impairment, gastric retention, untreated narrow-angle glaucoma, hypernasality, resting heart rate \\>100 bpm or systolic Blood Pressure \\>150 mmHg, a history of orthostatic hypotension or abnormal orthostatic blood pressure (change in mean arterial pressure \\[1\u002F3 systolic + 2\u002F3 diastolic\\] of \\> 20% between supine and standing blood pressures), known human immunodeficiency virus (i.e., by history), cirrhosis, biliary duct abnormalities, hepatobiliary carcinoma, symptomatic gallstone disease, active hepatic infections, history of bladder stones, recurrent urinary tract infections, or International Prostate Symptom Score \\> 7 or any one item \\> 2 (not including the nocturia item).\n6. Any material in the body that is a contraindication for MRI procedures or participated in prior nuclear medicine procedures in the past year that exceed FDA-defined limits when combined with radiation dosimetry from PET scanning in this protocol to avoid exceeding annual dosimetry limits (metal screener repeated before MRI scan during visit 2)\n7. Participants with suicidal ideation with intent or plan (indicated by affirmative answers to items 4 or 5 of the Suicidal Ideation section of the baseline C-SSRS) in the past 1 month or suicidal behavior in the past 3 months\n8. Laboratory abnormality that would compromise the well-being of the participant, including Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value \\> 2 times the upper limit of the laboratory normal reference range, elevated bilirubin (i.e., \\>2 x upper limit of normal (ULN)), or serum prostate specific antigen (PSA) \\>10 ng\u002Fml (for men only).\n9. A history of treatment resistance to antipsychotics\n10. Use of nicotine products within the previous month (prior to first PET scan)\n11. History of significant violent behavior when antipsychotic-free or currently homicidal\n12. Positive toxicology screen for any substances of abuse","50 Years",{"count":258,"type":22},12,[260,173],"PHASE1","This is a single site clinical trial in which 12 participants with schizophrenia will be randomized to one of three doses of treatment with Cobenfy for 5 weeks. \\[18F\\]DOPA PET scans will be obtained before and after treatment to examine the effects of Cobenfy on dopamine transmission.\n\nThe overall objective of the current study is to measure Cobenfy's ability to engage its putative target (DA transmission\u002Fsynthesis capacity in the striatum and midbrain as measured by \\[18F\\]DOPA Kicer (\\[18F\\]DOPA relative uptake rate)).",[29,176],[264,265,266],"Cobenfy","PET","MRI","2026-04-06",{"date":269,"type":40},"2026-04-13",{"date":100,"type":22},{"date":272,"type":22},"2027-12-31",{"name":274,"class":47},"New York State Psychiatric Institute",{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":280,"acronym":281,"eligibilityCriteria":282,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":169,"enrollmentInfo":283,"targetDuration":4,"studyType":23,"phases":285,"briefSummary":286,"conditions":287,"keywords":289,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":48},"100629033","non-invasive-brain-stimulation-using-tdcs-of-the-third-of-many-visual-pathways-100629033","NCT07469384","Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways","Sensory Contributions to Third Visual Pathway Dysfunction in Schizophrenia: Correlation and Causation","ButtomVP","Inclusion Criteria:\n\n1. Male or female subject, age 18-55\n2. Competent and willing to sign informed consent\n3. No more than moderately ill\n4. SCID DSM-5 diagnosis of Sz\u002FSzAff\n5. WAIS IQ \\>70\n6. Does not meet current criteria for DSM-5 defined substance abuse or dependence or have a history of diagnosis within past 6 months\n7. On medication within clinically approved range\n8. Does not meet criteria for another DSM-5 disorder other than those judged to be minor (e.g. simple phobia)\n\nExclusion Criteria:\n\n1. Significant neurological illness or history of significant head trauma\n2. Unstable physical illness or significant auditory\u002Fvisual deficits that might interfer\n3. Contraindication to MRI (e.g. metal implants, claustrophobia, pregnancy)\n4. Contraindications to tDCS including metal implant, pacemaker, history of seizure, traumatic brain injury or stroke\n5. Significant risk for suicide\n6. Has a history of an illness, disease, condition injury, or disability which, in the opinion of the principal investigator, may interfere with the completion of all study requirements per protocol, impact the quality of the data, or the validity of the study results, including unstable physical illness, significant neurological illness, significant head trauma\n7. Moderate or greater DSM-5 current substance use disorder, defined based on the presence of 4 or more of 11 substance use criteria within the past 12 months. In addition, individuals for whom substance use leads to not being able to perform work, home or school activities",{"count":284,"type":22},120,[25],"This study investigates the ability of transcranial direct current stimulation (tDCS) applied over the motion processing area of the brain (area MT) to improve face emotion recognition (FER) ability. tDCS is a type of non-invasive brain stimulation in which low level currents are applied over the scalp to influence underlying brain function. In schizophrenia, impaired ability to detect facial motion has been shown to contribute to impaired FER, which, in turn, leads to difficulties in social cognition and poor social outcome. The study will use both fMRI and EEG to measure brain function while participants view moving dot and dynamic face stimuli. Analyses will compare changes in fMRI and EEG activity in individuals receiving active vs. sham stimulation.",[29,288],"Schizo Affective Disorder",[290,291,292,293,294,295],"social cognition","fMRI","event-related potentials","motion detection","face emotion recognition","transcranial direct current stimulation","2026-03-10",{"date":298,"type":40},"2026-03-13",{"date":300,"type":40},"2026-02-01",{"date":302,"type":22},"2030-07",{"name":304,"class":47},"Nathan Kline Institute for Psychiatric Research",{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":4,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":312,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":4},"100627866","feasibility-acceptability-and-effectiveness-of-a-hatha-yoga-in-patients-hospitalized-for-schizophrenia-100627866","NCT07454200","Feasibility, Acceptability, and Effectiveness of a Hatha Yoga-in Patients Hospitalized for Schizophrenia","Feasibility, Acceptability, and Preliminary Effectiveness of a Hatha Yoga-on Reminiscence Functions and Mindfulness in Patients Hospitalized for Schizophrenia","Inclusion Criteria:\n\n* Patients are diagnosed with schizophrenia according to the DSM-5-TR or ICD-10 criteria\n* Patients are aged between 18 and 65 years old\n* Patients are clinically stabile, defined as being in the post-acute phase of care with no acute psychotic episode or psychiatric hospitalization within the 30 days preceding enrollment\n* Patients have adequate cognitive functioning, as evidenced by passing the Mini-Mental State Examination (MMSE), with sufficient insight and capacity to respond meaningfully to study procedures\n* Patients have the ability to attend group-based sessions and provide informed consent\n* Patients have the willingness and physical ability to engage safely in light-to-moderate yoga practice.\n\nExclusion Criteria:\n\n* Patients with severe cognitive impairment or intellectual disability that would disqualify meaningful participation\n* Patients with acute psychiatric symptoms or active suicidal ideation\n* Patients with physical limitations, such as a severe musculoskeletal condition, that would contraindicate safe participation in yoga practice.","64 Years",{"count":314,"type":22},36,[25],"The current study aims to examine the feasibility, acceptability, and preliminary effectiveness of a Hatha yoga-based group intervention on reminiscence functions and mindfulness in a sample of patients hospitalized for schizophrenia.",[29,318],"Hospitalized Adult Patients","2026-03-03",{"date":321,"type":40},"2026-03-06",{"date":323,"type":22},"2026-04-01",{"date":325,"type":22},"2027-12-01",{"name":327,"class":47},"The Hashemite University",{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":23,"phases":339,"briefSummary":340,"conditions":341,"keywords":344,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":48},"100611592","ps-trauma---development-of-trauma-treatment-for-patients-with-co-morbid-psychotic-disorders-and-traumas-100611592","NCT07242586","PS-Trauma - Development of Trauma Treatment for Patients With Co-morbid Psychotic Disorders and Traumas","PS-Trauma: Udvikling af Traumebehandling Til Psykiatriske Patienter Med Psykoselidelse - et Pilotstudie.","PS-Trauma","Inclusion Criteria:\n\n* over 18 years of age Diagnosis within schizophrenia spectrum (ICD10 F2X) PTSD symptoms equivalent to above 31 on the PCL-5 Included in Early intervention services (OPUS) Talks and understands Danish\n\nExclusion Criteria:\n\n* Substance or alcohol abuse interfering with the therapy Indication of sever cognitive impairment Changes in antipsychotic treatment within the last month","35 Years",{"count":338,"type":22},20,[25],"Overview:\n\nPeople with psychotic disorders frequently have a history of traumatic events such as neglect, bullying, or physical and sexual abuse. Many experience significant symptoms of post-traumatic stress, but trauma-focused treatment is rarely offered in standard psychiatric care. This pilot study investigates whether two established trauma therapies can be delivered safely and acceptably to young adults with psychotic disorders receiving care in the OPUS early-intervention program.\n\nObjectives:\n\nThe main aim is to evaluate the feasibility and acceptability of two trauma-focused treatments-Prolonged Exposure (PE) and Eye Movement Desensitization and Reprocessing (EMDR)-in patients with psychotic disorders and post-traumatic stress symptoms. The study is not designed to test treatment efficacy but to determine whether a larger randomized controlled trial is practical.\n\nStudy Design:\n\nThis is a pilot and feasibility study. Twenty OPUS patients with a diagnosis within the schizophrenia spectrum and clinically relevant PTSD symptoms will be randomly assigned to either PE or EMDR. All participants continue their usual OPUS care while attending weekly trauma-focused therapy sessions.\n\nAssessments:\n\nAt baseline and follow-up, participants complete clinical interviews and questionnaires assessing trauma symptoms, psychotic symptoms, functioning, well-being, recovery experiences, and possible negative effects. Instruments include the PCL-5, CAPS-5, Mini-TALE, PANSS-6, PSP, WHO-5, Brief INSPIRE-O, NEQ, and CSQ.\n\nPrimary Feasibility Outcomes:\n\nRecruitment: At least 80% of the planned sample enrolled within 6 months.\n\nRetention: At least 70% completing ≥12 therapy sessions.\n\nAcceptability: Participant satisfaction measured with the Client Satisfaction Questionnaire (CSQ).\n\nEligibility:\n\nInclusion:\n\nAge ≥18\n\nDiagnosis within the schizophrenia spectrum (ICD-10: F20-F29)\n\nPTSD symptom score \\>31 on PCL-5\n\nCurrent OPUS patient\n\nSufficient Danish language skills\n\nExclusion:\n\nSubstance use that prevents participation (e.g., attending sessions intoxicated)\n\nSevere cognitive impairment\n\nRecent changes in antipsychotic medication (within 1 month)\n\nRisks and Safety:\n\nTemporary increases in PTSD symptoms may occur when beginning trauma therapy; this pattern is well documented and typically followed by improvement. Previous studies show no higher risk of serious adverse events among patients with psychosis receiving trauma treatment compared with those who do not. Participants are closely monitored, and the study team works in continuous collaboration with OPUS clinicians. If a participant experiences significant clinical deterioration, the therapy can be paused or stopped, and supportive measures will be provided.\n\nPotential Benefits:\n\nParticipants may experience a reduction in trauma-related symptoms and gain access to a treatment that is not otherwise routinely offered to patients with psychotic disorders. The study may help improve future care for this underserved population.\n\nFunding:\n\nThe study is funded by the Nektar Foundation and conducted at the CORE Research Unit, Mental Health Services Copenhagen.",[29,342,343],"Schizotypal Disorder","Post Traumatic Stress Symptoms",[345,346,96,347,348,349],"First episode psychosis","Trauma","psychotherapy","prolonged exposure","EMDR","2025-12-03",{"date":352,"type":40},"2025-12-10",{"date":354,"type":40},"2025-10-02",{"date":356,"type":22},"2026-06-30",{"name":358,"class":47},"Nikolai Albert",{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":363,"acronym":4,"eligibilityCriteria":364,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":365,"targetDuration":4,"studyType":23,"phases":366,"briefSummary":367,"conditions":368,"keywords":371,"overallStatus":239,"whyStopped":4,"lastUpdateSubmitDate":375,"lastUpdatePostDateStruct":376,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":48},"100604059","the-effects-of-a-solution-focused-approach-on-psychosocial-adjustment-and-treatment-compliance-in-individuals-diagnosed-with-schizophrenia-100604059","NCT07144592","The Effects of a Solution-Focused Approach on Psychosocial Adjustment and Treatment Compliance in Individuals Diagnosed With Schizophrenia","Inclusion Criteria:\n\n* Having been diagnosed with schizophrenia according to DSM-5 diagnostic criteria,\n\nBeing between 18 and 65 years of age,\n\nBeing literate and verbally communicative,\n\nBeing clinically stable (not exhibiting symptoms of acute psychosis),\n\nBeing registered with a Community Mental Health Center (CMHC) and receiving regular services,\n\nBeing cognitively competent enough to participate in individual interviews during the research process,\n\nBeing an individual currently receiving psychiatric treatment and taking medication,\n\nAgreeing to participate voluntarily in the study and signing a written informed consent form.\n\nExclusion Criteria:\n\n* those who do not meet the inclusion criteria",{"count":21,"type":22},[25],"The aim of this study is to evaluate the effects of a solution-focused approach-based individual intervention on psychosocial adjustment and treatment adherence in individuals diagnosed with schizophrenia.\n\nThe study will be conducted as a randomized controlled trial including 60 clinically stable individuals diagnosed with schizophrenia according to DSM-5 criteria and registered at a Community Mental Health Center affiliated with a university hospital. Participants will be randomly assigned to an experimental group (n=30) and a control group (n=30).\n\nThe experimental group will receive one individual solution-focused therapy session per week for six weeks. The control group will receive usual care only. Data will be collected using a Personal Information Form, the Psychosocial Adjustment Scale (PSSAS), and the Medication Adherence Scale (MARS).",[29,369,370],"Psychosocial Adaptation","Treatment Adherence",[372,96,373,374],"treatment adherence","solution-focused therapy,","psychiatric nursing","2025-08-20",{"date":377,"type":40},"2025-08-27",{"date":379,"type":40},"2025-01-01",{"date":381,"type":22},"2025-10-25",{"name":383,"class":47},"Muş Alparslan University",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":83,"sex":17,"minAge":18,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":23,"phases":394,"briefSummary":395,"conditions":396,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":48},"100578952","disorders-of-the-sense-of-self-and-physical-activity-100578952","NCT06817980","Disorders of the Sense of Self and Physical Activity","sensdesoi","Inclusion Criteria:\n\n* Criteria common to all participants:\n* Men or women aged 18 to 60 inclusive\n* Subject affiliated to a health insurance scheme, beneficiary or beneficiary's beneficiary\n* Able to understand the aims and risks of the research, and to give informed consent\n* Visual acuity \\> 0.7 on the Freiburg Vision Test (Bach 1996) due to the use of visual equipment\n* BMI (body mass index) \\\u003C 40 (due to cardiovascular risk).\n\nPatient-specific criteria:\n\n* With schizophrenia: criteria for schizophrenia as defined in the DSMV (American Psychiatric Association, 2015)\n* With borderline personality disorder: criteria for borderline personality disorder as defined in the DSMV (American Psychiatric Association, 2015)\n* With vestibular disorders: peripheral vestibular disorders established after otolaryngological examination\n\nExclusion Criteria:\n\n* Criteria common to all participants:\n* Serious or unstabilized somatic pathology (including cardiovascular)\n* History likely to affect cerebral anatomy or to be linked to an abnormality (neonatal suffering, neurosurgical operation, comitiality, stroke...)\n* Presence of joint pain, likely to worsen after exercise\n* \\- Substance use disorders (as defined by DSM-IV TR)\n* 3D vision disorders as measured by the Wirt stereotest (depth perception at a disparity of at least 80'' arc)\n* Movement perception disorders (correct movement discrimination in less than 75% of trials (cf. § V-2.2)\n* History of general anaesthesia in the 3 months preceding the study\n* History of neurological disease\n* Impossibility of giving the subject informed information (subject in emergency situation)\n* Pregnancy declared by patient\n* Breast-feeding\n* Subject in exclusion period (determined by a previous or current study)\n* Subject hospitalized\n* Subject under court protection\n\nExclusion criteria specific to control subjects or patients with vestibular syndrome:\n\nHistory of major psychiatric pathology with current psychotropic medication (i.e., antidepressant, thymoregulator, antipsychotic)","60 Years",{"count":393,"type":22},168,[25],"Schizophrenia (SZ) patients with metabolic syndrome, patients with vestibular syndrome, and patients with borderline personality disorder, would benefit from physical activity (PA). Yet patient adherence to PA is low, at least in the case of SZ. the investigators work and the literature lead the investigators to consider that, in addition to motivational aspects, disorders of the bodily sense of self could play a role in this lack of adherence. Simply walking involves visual movements related to the self, which must be distinguished from movements in the environment. This means a distinction between self and not-self. Furthermore, these movements are all the more difficult to distinguish as they may also result from the fact that hidden objects become visible as a result of our own movement. In all sense-of-self disorders can themselves affect physical training, and the investigators will measure them in the first stage. In the second stage, the investigators will apply a standard, risk-free PA protocol by walking (3x3 sessions of 30 min). the investigators will test the impact of physical training on the sense of self under different conditions, with one environment minimizing self-related movement, vs. 2 environments with a variable level of enrichment (i.e. hidden objects inducing more or less self-related movement).\n\nAt the end of the protocol, the investigators will offer participants who wish to take part in an ancillary study, i.e. a walking session with mixed-reality goggles. These will superimpose a luminous flux on the periphery of the visual field. According to results obtained in the laboratory, this flux could restore sensory mechanisms impaired in schizophrenia. the investigators will use these glasses in the most difficult condition for the patient, and verify their impact.",[29,397,398],"Borderline Personality Disorder","Vestibular Syndromes","2025-08-01",{"date":401,"type":40},"2025-08-06",{"date":403,"type":22},"2025-09-01",{"date":405,"type":22},"2028-09-01",{"name":407,"class":47},"University Hospital, Strasbourg, France"]